<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Typhoid vaccine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Typhoid vaccine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Typhoid vaccine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10030" href="/d/html/10030.html" rel="external">see "Typhoid vaccine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11922" href="/d/html/11922.html" rel="external">see "Typhoid vaccine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F232369"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Typhim Vi;</li>
<li>Vivotif</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914279"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Typhim Vi;</li>
<li>Vivotif</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1041432"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Inactivated Bacteria</span>;</li>
<li>
<span class="list-set-name">Vaccine, Live Bacteria</span></li></ul></div>
<div class="block dop drugH1Div" id="F232374"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69dbd71f-7e60-4fa7-b336-19aa02cfbf67">Typhoid fever prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Typhoid fever prevention </b>
<b>(immunization): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Vivotif: Children ≥6 years and Adolescents: Primary immunization: Oral: One capsule (viable <i>S. typhi </i>Ty21a 2-10 × 10<sup>9</sup> colony-forming units) every other day for 4 doses (ie, days 1, 3, 5, and 7); all doses should be completed at least 1 week prior to potential exposure. <b>Note: </b>Optimal booster schedule has not been established; in trials, efficacy has been observed for at least 5 years. It is recommended to repeat primary immunization (all 4 doses) every 5 years for repeated or continued exposure. Canadian labeling allows use in children ≥5 years of age and recommends re-immunization every 7 years.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IM:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Typhim Vi: Children ≥2 years and Adolescents: Primary immunization: IM: 0.5 mL administered at least 2 weeks prior to expected exposure. <b>Note: </b>Optimal booster schedule has not been established; in trials, efficacy was reported for the 3-year trial duration. It is recommended to repeat primary immunization every 2 years if exposure is repeated or continued. Canadian labeling recommends re-immunization every 3 years.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193063"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193064"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F232371"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10030" href="/d/html/10030.html" rel="external">see "Typhoid vaccine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69dbd71f-7e60-4fa7-b336-19aa02cfbf67">Typhoid fever prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Typhoid fever prevention: </b></p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary immunization:</i> One capsule on alternate days (day 1, 3, 5, and 7) for a total of 4 doses; all doses should be complete at least 1 week prior to potential exposure</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Reimmunization (with repeated or continued exposure to typhoid fever):</i> Repeat full course of primary immunization every 5 years. Alternatively, in Canada, it is recommended to repeat a full course of primary immunization every 7 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CanImm.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CanImm.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IM:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i> 0.5 mL given at least 2 weeks prior to expected exposure</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Reimmunization (with repeated or continued exposure to typhoid fever):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Typhim Vi: 0.5 mL every 2 years (US labeling) or every 3 years (Canadian labeling)</p>
<p style="text-indent:-2em;margin-left:6em;">Typherix [Canadian product]: 0.5 mL every 3 years</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991152"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988506"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F232349"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>In the US, all serious adverse reactions must be reported to the Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Fesub%2Findex&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD%2B0my2cUJQ&amp;TOPIC_ID=13020" target="_blank">https://vaers.hhs.gov/esub/index</a>.</b> In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Injection (incidence may vary based on age and/or product used):</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Malaise (4% to 24%), headache (16% to 20%), generalized ache (1% to 13%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Tenderness at injection site (97% to 98%), pain at injection site (27% to 41%), induration at injection site (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Muscle tenderness (≤16%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (undefined 2% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pruritus (≤8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Nausea (≤8%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection site: Erythema at injection site (≤5%), swelling at injection site (≤4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Myalgia (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever greater than 100 to 101 degrees (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing and/or case reports: Abdominal pain, anaphylaxis, angioedema, arthralgia, asthma, diarrhea, dizziness, flu-like symptoms, Guillain-Barré syndrome, hypersensitivity reaction, hypotension, inflammation at injection site (including angioedema and urticaria), intestinal perforation (jejunum), loss of consciousness, lymphadenopathy, malaise, neck pain, serum sickness, skin rash, syncope (with and without convulsions), tremor, urticaria, vasodilation, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Central nervous system: Headache (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (6%), nausea (6%), diarrhea (3%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing and/or case reports: Anaphylaxis, demyelinating disease, myalgia, pain, rheumatoid arthritis, sepsis, urticaria, weakness</p></div>
<div class="block coi drugH1Div" id="F232361"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to any component of the vaccine. In addition, the oral vaccine is contraindicated with congenital or acquired immunodeficient state, acute febrile illness.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Canadian immunization guidelines also contraindicate oral typhoid vaccine in acute gastrointestinal conditions.</p></div>
<div class="block war drugH1Div" id="F232346"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Injection: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis, tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Injection: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: Injection: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]). Do not administer oral formulation during acute GI illness; vaccination may be deferred with persistent diarrhea or vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Injection: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Typhoid fever: Should not be used to treat typhoid fever or a chronic typhoid carrier. Not all recipients of typhoid vaccine will be fully protected against typhoid fever. Travelers should take all necessary precautions to avoid contact or ingestion of potentially contaminated food or water sources.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination with the inactive vaccine during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination or may have an adverse event secondary to replication. Live vaccine should generally not be administered. Household and close contacts of persons with altered immunocompetence may receive most age-appropriate vaccines (ACIP [Kroger 2023]; IDSA [Rubin 2014]). Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained. Live vaccines should be administered ≥4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block foc drugH1Div" id="F232355"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, enteric coated, Oral [live]:</p>
<p style="text-indent:-2em;margin-left:4em;">Vivotif: Viable <i>S. typhi</i> Ty21a 2-10 x 10<sup>9</sup> colony-forming units [contains lactose 180-200 mg/capsule and sucrose 3.3-34.2 mg/capsule]</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution [inactivated]:</p>
<p style="text-indent:-2em;margin-left:4em;">Typhim Vi: Purified Vi capsular polysaccharide 25 mcg/0.5 mL (0.5 mL, 10 mL) [derived from <i>S. typhi</i> Ty2 strain]</p></div>
<div class="block geq drugH1Div" id="F232342"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F3422285"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Typhim VI Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg/0.5 mL (per mL): $220.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Typhim VI Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg/0.5 mL (per 0.5 mL): $159.53</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52914280"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsule, enteric coated, Oral [live]:</p>
<p style="text-indent:-2em;margin-left:4em;">Vivotif: Viable <i>S. typhi</i> Ty21a 2-10 x 10<sup>9</sup> colony-forming units [contains lactose 180-200 mg/capsule and sucrose 3.3-34.2 mg/capsule]</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution:</p>
<p style="text-indent:-2em;margin-left:4em;">Typhim Vi: Vi capsular polysaccharide 25 mcg/0.5 mL (0.5 mL) [dreived from <i>S. typhi</i> Ty2 strain]</p></div>
<div class="block admp drugH1Div" id="F52613988"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer oral capsule 1 hour before a meal with a cold or lukewarm drink on alternate days; swallow capsule whole as soon as possible after placing in the mouth; do not open or chew capsule.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IM: Administer by IM injection into the anterolateral aspect of the thigh (children) or into the deltoid muscle; not for IV or SUBQ administration. If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). <b>Note:</b> For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">If purchased under Centers for Disease Control and Prevention contract, US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p></div>
<div class="block adm drugH1Div" id="F232358"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM: For IM administration. Administer as a single 0.5 mL (25 mcg) injection into the deltoid muscle. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013). Not for gluteal administration. Do not administer Typhim Vi or Typherix [Canadian product] intravascularly. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). <b>Note:</b> For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). If purchased under Centers for Disease Control and Prevention contract, US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Swallow capsule whole soon after placing into mouth; do not chew or open capsule. Capsule should be taken with a cold or lukewarm beverage (≤37°C/98.6°F). Take 1 hour prior to a meal. Avoid alcohol 1 hour before or 2 hours after administration; alcohol may disrupt the enteric coating.</p></div>
<div class="block sts drugH1Div" id="F232368"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Typhim Vi: Store between 2°C to 8°C (35°F to 46°F); do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">Vivotif: Store between 2°C to 8°C (35°F to 46°F).</p></div>
<div class="block meg drugH1Div" id="F25734165"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the United States, the appropriate Centers for Disease Control and Prevention (CDC)-approved Vaccine Information Statement (VIS) should be provided to the patient/caregiver before administering each dose of this vaccine. If purchased under CDC contract, the VIS must be provided and the VIS edition date and date it was provided to the patient/caregiver should be recorded. VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Ftyphoid.html&amp;token=LHu7kbGkhb1BRIgBifqmSqKWE4U5%2B3rWcSxWeY8RpP04bRpqrJwaPKECeqZvtpTvLMxUdTOOZbF4PofOpfXIuhA0i8kGRlde5pxOHvYVv1s%3D&amp;TOPIC_ID=13020" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/typhoid.html</a>.</p></div>
<div class="block usep drugH1Div" id="F53569387"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Active immunization to prevent disease from exposure to <i>Salmonella typhi.</i></p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral (Typhim Vi): FDA approved in ages ≥2 years and adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Live attenuated Ty21a vaccine (Vivotif): FDA approved in ages ≥6 years and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for the following patients (CDC/ACIP [Jackson 2015]):</p>
<p style="text-indent:-2em;margin-left:4em;">• Travelers to areas with a recognized risk of exposure to <i>S. typhi.</i></p>
<p style="text-indent:-2em;margin-left:4em;">• Persons with intimate exposure (eg, household contact) to a person with <i>S. typhi</i> fever or a known carrier.</p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory technicians with frequent exposure to <i>S. typhi.</i></p></div>
<div class="block cyt drugH1Div" id="F13300191"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F232350"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: May diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Typhoid Vaccine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Non-US labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment. US labeling states that safety and effectiveness of live vaccines administered with dimethyl fumarate has not been assessed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Etrasimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May diminish the therapeutic effect of Vaccines (Live).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Typhoid Vaccine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: May diminish the therapeutic effect of Typhoid Vaccine. This applies only to the oral (live) typhoid vaccine. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with proguanil. When possible, proguanil should not be started within 10 days of the last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Teplizumab may diminish the therapeutic effect of Typhoid Vaccine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezepelumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tildrakizumab: May enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tralokinumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Travelers' Diarrhea and Cholera Vaccine: Typhoid Vaccine may diminish the therapeutic effect of Travelers' Diarrhea and Cholera Vaccine.  Management: Separate the dosing of encapsulated oral typhoid vaccine and the oral travelers' diarrhea and cholera vaccine by at least 8 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: It is preferable to administer live vaccines simultaneously with tuberculin tests. If a live vaccine has been recently administered, the tuberculin skin test should be administered 4 to 6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F4039581"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. The manufacturer of the Typhim Vi injection suggests delaying vaccination until the second or third trimester if possible. Untreated typhoid fever may lead to miscarriage or vertical intrauterine transmission causing neonatal typhoid (rare).</p></div>
<div class="block mopp drugH1Div" id="F53569378"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">After injection, observe for hypersensitivity and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F232345"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Virulent strains of <i>Salmonella typhi</i> cause disease by penetrating the intestinal mucosa and entering the systemic circulation via the lymphatic vasculature. One possible mechanism of conferring immunity may be the provocation of a local immune response in the intestinal tract induced by oral ingesting of a live strain with subsequent aborted infection. The ability of <i>S. typhi</i> to produce clinical disease (and to elicit an immune response) is dependent on the bacteria having a complete lipopolysaccharide. The live attenuate Ty21a strain lacks the enzyme UDP-4-galactose epimerase so that lipopolysaccharide is only synthesized under conditions that induce bacterial autolysis. Thus, the strain remains avirulent despite the production of sufficient lipopolysaccharide to evoke a protective immune response. Despite low levels of lipopolysaccharide synthesis, cells lyse before gaining a virulent phenotype due to the intracellular accumulation of metabolic intermediates.</p></div>
<div class="block phk drugH1Div" id="F232360"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Immunity to <i>Salmonella typhi</i>: Oral: ~1 week after completing the series; Parenteral: Antibody response develops within 2 weeks after a single dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Immunity: Oral: &gt;5 years; Parenteral: Typhim Vi: ~2 years.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539952"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vivotif</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vaccin Typhim VI | Vivotif</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Typh-vax | Typherix | Typhim vi | Vivotif | Vivotif oral</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vaxphoid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Typherix</span>;</li>
<li>
<span class="countryCode">(BO)</span> <span class="country">Bolivia, Plurinational State of</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi | Vacina febre tifoide</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Typbar | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Vi polysaccharide typhoid vaccine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif | Vivotif berna</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Typhoral l | Vivotif</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif berna</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Vivotif berna</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Typherix vi</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bio typh | Biovac tcv | Biovac typhoid | Typbar | Typherix | Typhim vi | Tyvax-vi plus | Vactyph</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Neotyf | Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Typbar | Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vivotif | Zerotyph | Zerotyph II</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Tifovax | Typhim vi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhovax | Vaccin Typhim VI | Vivotif</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif berna</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Typh-vax | Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Typbar | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif berna | Zerotyph</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Typbar | Typherix | Typhim vi | Zerotyph</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vaccin Typhim VI | Vivotif berna</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Vaccin Typhim VI</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi | Vivotif</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Typbar | Typhim vi | Vivotif | Vivotif berna</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Typbar | Typhim vi</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Typhim</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Typherix | Typhim vi | Vivotif berna</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Typhim vi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-14999618">
<a name="14999618"></a>Begier EM, Burewn DR, Haber P, et al, “Postmarketing Safety Surveillance for Typhoid Fever Vaccines From the Vaccine Adverse Event Reporting System, July 1990 Through June 2002,” <i>Clin Infect Dis</i>, 2004, 38(6):771-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/14999618/pubmed" id="14999618" target="_blank">14999618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CanImm.1">
<a name="CanImm.1"></a>Canadian Immunization Guide. Public Health Agency of Canada. Updated October 31, 2023. Accessed December 4, 2023. <a href="https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html" target="_blank">https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303‐306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2647863">
<a name="2647863"></a>Ferreccio C, Levine MM, Rodriguez, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: A field trial in an endemic area. <i>J Infect Dis</i>. 1989;159(4):766-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/2647863/pubmed" id="2647863" target="_blank">2647863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc (2003)</i>. 2013;53(1):102‐103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16278037">
<a name="16278037"></a>Guzman CA, Borsutzky S, Griot-Wenk M, et al, “Vaccines Against Typhoid Fever,” <i>Vaccine</i>, 2006, 24(18):3804-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/16278037/pubmed" id="16278037" target="_blank">16278037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25811680">
<a name="25811680"></a>Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine – advisory committee on immunization practices, United States, 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):305-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/25811680/pubmed" id="25811680" target="_blank">25811680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>. Accessed October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12456854">
<a name="12456854"></a>Parry CM, Hien TT, Dougan G, et al, “Typhoid Fever,” <i>N Engl J Med</i>, 2002, 347(22):1770-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/12456854/pubmed" id="12456854" target="_blank">12456854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/typhoid-vaccine-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Typherix.1">
<a name="Typherix.1"></a>Typherix (typhoid vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TyphimVi.1">
<a name="TyphimVi.1"></a>Typhim Vi (typhoid vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TyphimVi.2">
<a name="TyphimVi.2"></a>Typhim Vi (typhoid vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Limited; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vivotif.1">
<a name="Vivotif.1"></a>Vivotif (typhoid vaccine) [prescribing information]. Redwood City, CA: Emergent Travel Health Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vivotif.2">
<a name="Vivotif.2"></a>Vivotif (typhoid vaccine) [product monograph]. Mississauga, Ontario, Canada: Quality and Compliance Services Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vivotif.3">
<a name="Vivotif.3"></a>Vivotif (typhoid vaccine) [product monograph]. Mississauga, Ontario, Canada: Quality and Compliance Services Inc; November 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13020 Version 208.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
